A Computational Model of Loss of Dopaminergic Cells in Parkinson's Disease Due to Glutamate-Induced Excitotoxicity
Overview
Authors
Affiliations
Parkinson's disease (PD) is a neurodegenerative disease associated with progressive and inexorable loss of dopaminergic cells in Substantia Nigra pars compacta (SNc). Although many mechanisms have been suggested, a decisive root cause of this cell loss is unknown. A couple of the proposed mechanisms, however, show potential for the development of a novel line of PD therapeutics. One of these mechanisms is the peculiar metabolic vulnerability of SNc cells compared to other dopaminergic clusters; the other is the SubThalamic Nucleus (STN)-induced excitotoxicity in SNc. To investigate the latter hypothesis computationally, we developed a spiking neuron network-model of SNc-STN-GPe system. In the model, prolonged stimulation of SNc cells by an overactive STN leads to an increase in 'stress' variable; when the stress in a SNc neuron exceeds a stress threshold, the neuron dies. The model shows that the interaction between SNc and STN involves a positive-feedback due to which, an initial loss of SNc cells that crosses a threshold causes a runaway-effect, leading to an inexorable loss of SNc cells, strongly resembling the process of neurodegeneration. The model further suggests a link between the two aforementioned mechanisms of SNc cell loss. Our simulation results show that the excitotoxic cause of SNc cell loss might initiate by weak-excitotoxicity mediated by energy deficit, followed by strong-excitotoxicity, mediated by a disinhibited STN. A variety of conventional therapies were simulated to test their efficacy in slowing down SNc cell loss. Among them, glutamate inhibition, dopamine restoration, subthalamotomy and deep brain stimulation showed superior neuroprotective-effects in the proposed model.
Zhang Q, Liu Q, Bi Y Cogn Neurodyn. 2024; 18(5):2243-2261.
PMID: 39555276 PMC: 11564637. DOI: 10.1007/s11571-024-10071-7.
Parkinson's Disease Risk and Hyperhomocysteinemia: The Possible Link.
Al-Kuraishy H, Al-Gareeb A, Elewa Y, Zahran M, Alexiou A, Papadakis M Cell Mol Neurobiol. 2023; 43(6):2743-2759.
PMID: 37074484 PMC: 10333143. DOI: 10.1007/s10571-023-01350-8.
Schumm S, Gabrieli D, Meaney D Front Cell Neurosci. 2022; 16:977769.
PMID: 36505514 PMC: 9729278. DOI: 10.3389/fncel.2022.977769.
Hassan S, Samanta S, Dash R, Karpinski T, Habibi E, Sadiq A Front Pharmacol. 2022; 13:1015835.
PMID: 36299900 PMC: 9589363. DOI: 10.3389/fphar.2022.1015835.
Santiago-Castaneda C, Huerta de la Cruz S, Martinez-Aguirre C, Orozco-Suarez S, Rocha L Pharmaceutics. 2022; 14(8).
PMID: 36015236 PMC: 9414526. DOI: 10.3390/pharmaceutics14081609.